Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial 1: Primary outcomes

Go back to Resources

Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial 1: Primary outcomes

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

ROP outcome in infants with prethreshold ROP and SpO2 ›94% in room air

Go back to Resources

ROP outcome in infants with prethreshold ROP and SpO2 ›94% in room air

Authors:

Location:

Go back to Resources

Risk factors associated with age-related macular degeneration. A case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report No. 3

Go back to Resources

Risk factors associated with age-related macular degeneration. A case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report No. 3

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Review of the COBLT Study Processing Procedures

Go back to Resources

Review of the COBLT Study Processing Procedures

Authors:

Location:

Go back to Resources

Reproducibility of p53 immunohistochemistry in bladder tumors

Go back to Resources

Reproducibility of p53 immunohistochemistry in bladder tumors

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Randomized trial of tacrolimus (PROGRAF™) in combination with azathioprine or mychophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation

Go back to Resources

Randomized trial of tacrolimus (PROGRAF™) in combination with azathioprine or mychophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

randomized prospective multicenter trial of T-cell antibody induction therapy in pediatric renal transplantation

Go back to Resources

randomized prospective multicenter trial of T-cell antibody induction therapy in pediatric renal transplantation

Authors:

Location:

Go back to Resources

Primary immunosuppressive agent does not affect Hepatitis C recurrence rates following liver transplantation

Go back to Resources

Primary immunosuppressive agent does not affect Hepatitis C recurrence rates following liver transplantation

Authors:

Location:

Go back to Resources

Pregnancy outcomes in healthy nulliparas who developed hypertension

Go back to Resources

Pregnancy outcomes in healthy nulliparas who developed hypertension

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Overcoming recruitment roadblocks created by healthcare changes

Go back to Resources

Overcoming recruitment roadblocks created by healthcare changes

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 126
  • Page 127
  • Page 128
  • Page 129
  • Current page 130
  • Page 131
  • Page 132
  • Page 133
  • Page 134
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification